GeoVax Labs EBITDA 2010-2025 | GOVX

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

GeoVax Labs ebitda from 2010 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

GeoVax Labs ebitda from 2010 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$246.7B
Amgen (AMGN)	$159.1B
Gilead Sciences (GILD)	$146.4B
Vertex Pharmaceuticals (VRTX)	$100.2B
Bristol Myers Squibb (BMY)	$98.4B
GSK (GSK)	$80.7B
CSL (CSLLY)	$70.8B
Regeneron Pharmaceuticals (REGN)	$60.6B
Alnylam Pharmaceuticals (ALNY)	$60.1B
Argenex SE (ARGX)	$40.2B
Insmed (INSM)	$26.9B
BioNTech SE (BNTX)	$26.8B
Royalty Pharma (RPRX)	$21B
Biogen (BIIB)	$20.4B
Incyte (INCY)	$16.7B
Illumina (ILMN)	$15.6B
Genmab (GNMSF)	$15.3B
Genmab (GMAB)	$15.3B
Ascendis Pharma (ASND)	$11.9B
BioMarin Pharmaceutical (BMRN)	$11B
QIAGEN (QGEN)	$10.9B
Moderna (MRNA)	$10.9B
Swedish Orphan Biovitrum (BIOVF)	$10.3B
Exelixis (EXEL)	$10.1B
Verona Pharma American Depositary Share (VRNA)	$9B
Exact Sciences (EXAS)	$8.6B
Bio-Techne Corp (TECH)	$8.6B
Blueprint Medicines (BPMC)	$8.3B
Halozyme Therapeutics (HALO)	$8.2B
Roivant Sciences (ROIV)	$8B